SoniVie Receives FDA Breakthrough Device Designation For The TIVUS System In The Treatment Of Pulmonary Arterial Hypertension (PAH)
SoniVie, an Israeli company developing a novel system for the treatment of PAH, today announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the Therapeutic Intra-Vascular Ultrasound (TIVUS) System in patients